Phase 4 trial to assess if high cortisol levels common with type 2 diabetes
A Phase 4 clinical trial will assess the prevalence of excessive cortisol, or hypercortisolism, in people with difficult-to-treat type 2 diabetes, and the effectiveness of Korlym (mifepristone) in lowering cortisol levels, Corcept Therapeutics announced. The two-part, placebo-controlled CATALYST (NCT05772169) study is expected to enroll up to…